Deutsche Bank's Roche upgrade on October 23, 2026, moved the Swiss healthcare company to Buy from Hold and raised its price target to CHF 500 from CHF 340. The more positive recommendation comes as Roche approaches two scheduled U.S. regulatory decisions for its investigational breast cancer drug giredestrant.
Key Takeaways
- Deutsche Bank raised its Roche price target by CHF 160 alongside the upgrade to Buy.
- Roche's phase III evERA study showed longer progression-free survival with a giredestrant combination.
- FDA target decision dates are November 30 and December 18, 2026, for separate breast cancer applications.
Table of Contents
- Roche upgrade follows a strong year for the shares
- Giredestrant results provide clinical context
- Two FDA decisions are the next milestones
- Conclusion
Roche upgrade follows a strong year for the shares
The new target is about 47% higher than Deutsche Bank's previous CHF 340 estimate. It represents the bank's assessment, not a Roche earnings forecast or a guaranteed future share price.
Roche's U.S.-traded RHHBY shares were quoted at $59.62 in the October 23 update, following a 43% gain over the preceding year. That left them close to their 52-week high. The dollar-denominated RHHBY quote and the Swiss-franc price target should not be compared directly to calculate potential returns.
| Item | Details |
|---|---|
| RHHBY quoted price | $59.62 in the October 23, 2026 update |
| 52-week high | $60.85 |
| Trailing price-to-earnings ratio | 25.58, compared with a five-year median of 19.95 |
| Dividend yield | 2.59% in the October 23 update |
Giredestrant results provide clinical context
Roche's October 1 giredestrant trial update described positive phase III evERA results in advanced breast cancer. The study compared giredestrant plus everolimus with standard endocrine therapy plus everolimus in patients previously treated with a CDK4/6 inhibitor and endocrine therapy.
In the overall study population, median progression-free survival was 8.8 months with the giredestrant combination, versus 5.5 months in the comparator group. Among patients with ESR1 mutations, the corresponding figures were 10.0 months and 5.5 months.
These findings concern the time before disease progression or death, rather than a demonstrated overall-survival benefit. Roche said overall-survival data remained immature and follow-up would continue. The clinical announcement provides context for the drug's development but does not establish Deutsche Bank's valuation assumptions.
Two FDA decisions are the next milestones
Roche said the FDA had set a November 30, 2026, target decision date for giredestrant as an adjuvant treatment in early-stage breast cancer. A separate application for giredestrant combined with everolimus in specified patients with advanced disease has a December 18, 2026, target date.
The applications cover different treatment settings. Acceptance for review and a target decision date do not constitute approval; giredestrant remained investigational in Roche's October 1 announcement.
Conclusion
The Roche upgrade raises Deutsche Bank's valuation target substantially after a strong year for the shares. The next confirmed milestones are the FDA's scheduled target decision dates for giredestrant, beginning November 30, 2026.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
